参考文献/References:
[1] Gill JS,Hunter GJ,Gane G,et al.Heterogeneity of the human myocardial sympathetic innervation:in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy.Am Heart J,1993,126(2):390-398.
[2] Estorch M,Serra-Grima R,Flotats A,et al.Myocardial sympathetic innervation in the athlete’s sinus bradycardia:is there selective inferior myocardial wall denervation?.J Nucl Cardiol,2000,7(4):354-358.
[3] Ogita H,Shimonagata T,Fukunami M,et al.Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure:a prospective study.Heart,2001,86(6):656-660.
[4] Merlet P,Valette H,Dubois-Rande JL,et al.Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.J Nucl Med,1992,33(4):471-477.
[5] Merlet P,Pouillart F,Dubois-Rande’ L,et al.Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart.J Nucl Med,1999,40(2):224-231.
[6] Takeishi Y,Atsumi H,Fujiwara S,et al.ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure.J Nucl Med,1997,38(7):1085-1089.
[7] Matsui T,Tsutamoto T,Maeda K,et al.Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors.Circ J,2002,66(6):537-543.
[8] Merlet P,Benvenuti C,Moyse D,et al.Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy.J Nucl Med,1999,40(6):917-923.
[9] Zipes DP,Camm AJ,Borggrefe M,et al.ACC/AHA/ESC 2006guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for PracticeGuidelines(Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death).J Am Coll Cardiol,2006,48(5):e247-e346.
[10] Bardy GH,Lee KL,Mark DB,et al.Amiodarone or an implantable defibrillator for congestive heart failure.N Engl J Med,2005,352(3):225-237.
[11] Arora R,Ferrick KJ,Nakata T,et al.I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator.J Nucl Cardiol,2003,10(2):121-131.
[12] Nagahara D,Nakata T,Hashimoto A,et al.Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function.J Nucl Med,2008,49(2):225-233.
[13] Kioka H,Yamada T,Mine T,et al.Prediction of sudden death inpatients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging.Heart,2007,93(10):1213-1218.
[14] Zipes DP.Influence of myocardial ischemia and infarction on autonomic innervation of heart.Circulation,1990,82(4):1095-1105.
[15] Dae MW,Herre JM,O’Connell JW,et al.Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction.J Am Coll Cardiol,1991,17(6):1416-1423.
[16] Simôes MV,Barthel P,Matsunari I,et al.Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised,acute myocardial infarction.Eur Heart J,2004,25(7):551-557.
[17] Sasano T,Abraham R,Chang KC,et al.Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction.J Am Coll Cardiol,2008,51(23):2266-2275.
[18] Tomoda H,Yoshioka K,Shiina Y,et al.Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina.Am Heart J,1994,128(3):452-458.
[19] Simula S,Vanninen E,Viitanen L,et al.Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary disease.J Nucl Med,2002,43(1):1-7.
[20] Hattori N,Tamaki N,Hayashi T,et al.Regional abnormality of iodine-123-MIBG in diabetic hearts.J Nucl Med,1996,37(12):1985-1990.
[21] Nagamachi S,Fujita S,Nishii R,et al.Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus.J Nucl Cardiol,2006,13(1):34-42.
[22] Gill JS,Hunter GJ,Gane J,et al.Asymmetry of cardiac[123I] metaiodobenzylguanidine scans in patients with ventricular tachy-cardia and a "clinically normal" heart.Br Heart J,1993,69(1):6-13.
[23] Wakasugi S,Fischman AJ,Babich JW,et al.Metaiodobenzylguanidine:evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy.J Nucl Med,1993,34(8):1283-1286.
[24] Carrió I,Estorch M,Bemá L,et al.Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity.J Nucl Med,1995,36(11):2044-2049.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]